Mixed solvent mutually enhanced transdermal therapeutic system

• US 5,064,654 A
• Filed: 04/20/1990
• Issued: 11/12/1991
• Est. Priority Date: 01/11/1989
• Status: Expired due to Term

• Current Assignee: Novartis Corporation (Novartis Ag)
• Original Assignee: Ciba-Geigy Corporation (Novartis Ag)
• Inventors: Berner, Bret, Ebert, Charles, Mazzenga, Gerard C., Otte, John H.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): BROUILLETTE, D GABRIELLE
• Application Number:
  US07/512,639
• Time in Patent Office: 571 Days
• Field of Search: 424/443, 424/447, 424/448, 424/449, 604/304, 604/897
• US Class Current: 424/448
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

The invention relates to the art of transdermal administration of drug substances, particularly those drug substances having a greater solubility in ethanol than in water and those drug substances having cationic or anionic substituent groups. It is especially useful for the administration of nitroglycerin.

Claims

1. A transdermal drug delivery system comprising

(i) an occlusive, impermeable polymeric backing layer;

(ii) a drug depot on one side thereof;

(iii) a removable, occlusive covering layer over said drug depot; and

(iv) an adhesive means by which said delivery system, absent said removable covering layer may be affixed to an intended patient;

said drug depot containing a drug formulation comprising a transdermally administrable pharmaceutically acceptable pharmaceutically active agent or a precursor thereof, water and ethanol said active agent or precursor thereof being present in a pharmaceutically effective amount;

said ethanol and said water being present in a volume;

volume ratio of from 30;

70 up to less than 95;

5 such that said ethanol, water and drug are delivered to a patient'"'"'s skin, which patient has applied said system absent said removable covering layer to said patient'"'"'s skin, in amounts that said drug is delivered in a transdermally administrable efficacious amount, said water has an activity at said patients skin of about 0.4 to about 0.95 and said ethanol, at said patient'"'"'s skin, has an activity of 0.3 to about 0.9, and wherein, once applied to said patient'"'"'s skin, said ethanol has a flux from said system to said skin of at least 1500 mcg/cm² /hr and through said skin of at least 1500 mcg/cm² /hr.

2. The system of claim 1 wherein said composition further comprises at least one further transdermal drug delivery device acceptable adjuvant.

3. The system of claim 1 wherein said volume:

volume ratio is from 45;

55 up to and including 85;

15.

4. The system of claim 5 wherein said volume:

volume ratio is from 65;

35 up to and including 75;

25.

5. The system of claim 1 wherein said water and ethanol are delivered to said patient'"'"'s skin so as to result in an ethanol activity of at least 0.5.

6. The system of claim 1 wherein, once applied to a patient'"'"'s skin, said alkanol ethanol has a potential flux through said skin of at least 1500 mcg/cm² /hr, and an actual flux from said system through said skin of at least 900 mcg/cm² /hr, and at least 50% of the diffusional resistance is provided by said system.

7. A dosage form for transdermally administering a pharmaceutically active agent which dosage form comprises

a) an impermeable backing,

b) a rate-controlling membrane of polyurethane or ethylene/vinylacetate of greater than 20% vinyl acetate and from 0.5 to 10.0 mils thick,

c) a silicone-based or acrylic-based pressure-sensitive adhesive on said rate controlling membrane distal from said backing,

d) a reservoir formed by a and b,

e) an aqueous pharmaceutically acceptable lower alkanol reservoir composition having a volume fraction of said ethanol of from 0.35 to 0.9 calculated based on said ethanol alkanol and water only, and

f) said pharmaceutically active agent.

8. The dosage form of claim 7 further comprising a salt of said pharmaceutically active agent or a buffering agent in said adhesive.

9. A dosage form of claim 7 wherein the membrane is microporous and the adhesive is pressure-sensitive.

10. A dosage form of claim 7 where the membrane allows said ethanol to permeate therethrough between 1.5 and 12 mg/cm² /hr and water to permeate therethrough at between 0.5-10 mg/cm² /hr and the adhesive is pressure-sensitive.

11. A unit dosage form according to claim 7 wherein said membrane is impermeable to said pharmaceutically active agent and said adhesive contains said pharmaceutically active agent.